Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Pharmacologic modulation of RNA splicing enhances anti-tumor immunity.

ABSTRACT: Pharmacologic modulation of RNA splicing enhances anti-tumor immunity.

PROVIDER: PRJNA683080 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR13211940_1.fastq.gz	Fastqsanger.gz
	SRR13211940_2.fastq.gz	Fastqsanger.gz
	SRR13211941_1.fastq.gz	Fastqsanger.gz
	SRR13211941_2.fastq.gz	Fastqsanger.gz
	SRR13211942_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 96

Similar Datasets

Pharmacologic modulation of RNA splicing enhances anti-tumor immunity.

Project description:Although mutations in DNA are the best-studied source of neoantigens that determine response to immune checkpoint blockade, alterations in RNA splicing within cancer cells could similarly result in neoepitope production. However, the endogenous antigenicity and clinical potential of such splicing-derived epitopes have not been tested. Here, we demonstrate that pharmacologic modulation of splicing via specific drug classes generates bona fide neoantigens and elicits anti-tumor immunity, augmenting checkpoint immunotherapy. Splicing modulation inhibited tumor growth and enhanced checkpoint blockade in a manner dependent on host T cells and peptides presented on tumor MHC class I. Splicing modulation induced stereotyped splicing changes across tumor types, altering the MHC I-bound immunopeptidome to yield splicing-derived neoepitopes that trigger an anti-tumor T cell response in vivo. These data definitively identify splicing modulation as an untapped source of immunogenic peptides and provide a means to enhance response to checkpoint blockade that is readily translatable to the clinic.

2021-06-30 | GSE162818 | GEO

Pharmacologic modulation of RNA splicing enhances anti-tumor immunity.

| S-EPMC8684350 | biostudies-literature

BET Inhibition Enhances TNF Mediated Anti-Tumor Immunity

Project description:BET Inhibition Enhances TNF Mediated Anti-Tumor Immunity

| PRJNA765317 | ENA

Epigenetic priming enhances anti-tumor immunity in resistant ovarian cancer

Project description:Epigenetic priming enhances anti-tumor immunity in resistant ovarian cancer

| PRJNA778066 | ENA

BET Inhibition Enhances TNF Mediated Anti-Tumor Immunity [RNA-Seq]

Project description:BET Inhibition Enhances TNF Mediated Anti-Tumor Immunity [RNA-Seq]

| PRJNA765320 | ENA

Physiologic expression of Sf3b1K700E causes impaired erythropoieses, aberrant splicing, and sensitivity to pharmacologic spliceosome modulation

Project description:Physiologic expression of Sf3b1K700E causes impaired erythropoieses, aberrant splicing, and sensitivity to pharmacologic spliceosome modulation

| PRJNA339149 | ENA

Epigenetic priming enhances anti-tumor immunity in resistant ovarian cancer [array]

Project description:Epigenetic priming enhances anti-tumor immunity in resistant ovarian cancer [array]

| PRJNA776250 | ENA

Dnase1l3 enhances antitumor immunity and suppresses tumor progression

Project description:Dnase1l3 enhances antitumor immunity and suppresses tumor progression

| PRJNA803220 | ENA

BET Inhibition Enhances TNF Mediated Anti-Tumor Immunity [ChIP-Seq, ATAC-Seq]

Project description:BET Inhibition Enhances TNF Mediated Anti-Tumor Immunity [ChIP-Seq, ATAC-Seq]

| PRJNA765322 | ENA

Epigenetic priming enhances anti-tumor immunity in resistant ovarian cancer [RNA-Seq]

Project description:Epigenetic priming enhances anti-tumor immunity in resistant ovarian cancer [RNA-Seq]